Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy arena. The therapy was cleared to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) after showing complete remission in 63% of efficacy evaluable patients during Autolus’ FELIX study. Aucatyzl will be manufactured at the drugmaker’s Stevenage, U.K. site dubbed “the Nucleus” with Cardinal Health serving as the U.S. commercial distribution partner. Source: Fierce Pharma 11/11/2024